owned 3.31% of ProPhase Labs worth $3,588,000 at the end of the most recent reporting period. The fund owned 512,609 shares of the company's stock after purchasing an additional 14,671 shares during the quarter. ( NASDAQ:PRPH - Get Rating) by 2.9% during the 1st quarter, according to the company in its most recent filing with the SEC. lifted its position in ProPhase Labs, Inc. Institutional Investors Weigh In On ProPhase LabsĪn institutional investor recently raised its position in ProPhase Labs stock. The ex-dividend date of this dividend was Tuesday, May 24th. Investors of record on Wednesday, May 25th were paid a dividend of $0.30 per share. The business also recently announced a dividend, which was paid on Friday, June 3rd. The company has a current ratio of 3.67, a quick ratio of 3.43 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average of $11.50 and a 200 day moving average of $8.67. ProPhase Labs has a twelve month low of $4.76 and a twelve month high of $15.25. The stock has a market capitalization of $173.95 million, a price-to-earnings ratio of 11.14 and a beta of -0.36. 547 shares of the company traded hands, compared to its average volume of 260,525. NASDAQ:PRPH traded up $0.42 during trading hours on Friday, hitting $11.23. On average, analysts expect ProPhase Labs to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year. ProPhase Labs had a net margin of 15.91% and a return on equity of 25.26%. The firm had revenue of $47.53 million during the quarter, compared to analysts' expectations of $24.31 million. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.39 by $0.29. ProPhase Labs ( NASDAQ:PRPH - Get Rating) last released its earnings results on Friday, May 13th. Analysts expect ProPhase Labs to post earnings of $0.12 per share for the quarter. ProPhase Labs ( NASDAQ:PRPH - Get Rating) will post its quarterly earnings results before the market opens on Thursday, August 11th.

7 Commodities ETFs to Help Build a Hedge Against Inflation.

7 Dividend Stocks That Earn 10% Every Month.

7 Dividend Aristocrats to Help You Take the Bite Out of the Bear.

10 Recession-Proof Stocks That Will Let You Wait Out the Bear.7 Stocks with the Pricing Power to Push Through High Inflation.7 Blue-Chip Dividend Stocks That Won’t be Impacted by Rising Interest Rates.7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time.7 Stocks to Buy to Outrun Rising Interest Rates.7 Sports Betting Stocks to Buy for Their Long-Term Possibilities.7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom.Do These Dividend Achievers Deserve A Place In Your Portfolio?.3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns.Three Value Stocks For A Volatile Market.The Two Things You Need To Know About Oracle’s FQ1 Report.This Is What To Expect From The S&P 500 Now.These 3 Reports Will Tell Us Much About the Current Economy.Is Five Below Trying to Punch Too High?.Can Health Drink Maker Celsius Outrun Its Monster Rival?.

It’s Time To Embrace Another 25% Decline In The S&P 500.Is Lyft Going To Make It As Acquisition Rumors Swirl?.The Trader's Guide to Equities Research.

Prophase labs stock